- Cefuroxime is indicated for skin and soft tissue infection caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp.
- Based on our NAG 08, it can be used as an alternative for S.aureus infection in boils/carbuncles. Cefuroxime 500mg PO q12h for 7-10 days
- Based on the coverage, can also be used as alternatives for Impetigo/cellulitis/erysipelas [S.aureus and S.pyogenes]
- Based on IDSA 2014, Cefuroxime is also indicated for skin and tissue infection from human and animal bites.
Antibiotic Coverage :
Aerobes,
Gram-positive:
Staphylococcus
aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes (and other streptococci).
Aerobes, Gram-negative:
Citrobacter spp., Enterobacter spp., Escherichia
coli, Haemophilus influenzae (including ampicillin-resistant
strains), Haemophilus
parainfluenzae, Klebsiella spp.
(including Klebsiella
pneumoniae), Moraxella (Branhamella) catarrhalis (including
ampicillin- and cephalothin-resistant strains), Morganella
morganii (formerly Proteus
morganii), Neisseria gonorrhoeae (including penicillinase- and
non–penicillinase-producing strains), Neisseria meningitidis, Proteus mirabilis, Providencia
rettgeri (formerly Proteus
rettgeri), Salmonella spp.,
and Shigella spp.
Anaerobes:
Gram-positive
and gram-negative cocci (including Peptococcus andPeptostreptococcus spp.), gram-positive bacilli
(including Clostridium spp.), and gram-negative bacilli
(including Bacteroides and Fusobacterium spp.).
- www.drugs.com
- IDSA Practice Guidelines for SSTIs (2014)
- National Antibiotic Guideline (2008)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.